1
Ernst Glen, Phillips Eifion, Schmiesing Richard: Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists. Astrazeneca, Ernst Glen, Phillips Eifion, Schmiesing Richard, ASTRAZENECA, February 26, 2004: WO/2004/016617 (40 worldwide citation)

Nicotinic acetylcholine receptor of formula (I) wherein D, Ar1, E and Ar2 are as defined in the specification, enantiomers, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same in the treatment or prophylaxis of psychotic disorde ...


2
Ernst Glen, Phillips Eifion, Schmiesing Richard: Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.. Astrazeneca, Ernst Glen, Phillips Eifion, Schmiesing Richard, ASTRAZENECA, February 26, 2004: WO/2004/016616 (37 worldwide citation)

Nicotinic acetylcholine receptor agonists of formula I wherein a, b, c, D and R are as defined in the specification, enantiomers, pharmaceutically- acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same in the treatment or prophylaxis of psychotic ...


3
Chang Hui Fang, Phillips Eifion: Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor. Astrazeneca, Astrazeneca, Chang Hui Fang, Phillips Eifion, ASTRAZENECA, January 20, 2005: WO/2005/005435 (25 worldwide citation)

Compounds of formula (I) and pharmaceutically-acceptable salts thereof, wherein Arl, A and Ar2 are as defined in the specification, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeut ...


4

5
Chapdelaine Marc, Chang Hui Fang, Herzog Keith J, Horchler Carey, Phillips Eifion: Nicotinic acetylcholine receptor ligands. Astrazeneca, Chapdelaine Marc, Chang Hui Fang, Herzog Keith J, Horchler Carey, Phillips Eifion, ASTRAZENECA, June 22, 2006: WO/2006/065209 (14 worldwide citation)

Acetylcholine receptor ligands of formula I wherein A, Ar1 and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.


6
Phillips Eifion, Mack Robert, Macor John, Semus Simon: Novel spiroazabicyclic heterocyclic compounds. Astra, May 3, 2000: EP0996622-A1 (12 worldwide citation)

A compound of formula (I) wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H2 or F2; A is N or C(R); G is N or C(R); D is N or C(R); with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen o ...


7
Chang Hui Fang, Holmquist Christopher, Phillips Eifion, Piser Timothy, Simpson Thomas, Urbanek Rebecca, Woods James, Xiong Hui: Nicotinic acetylcholine receptor ligands 101. Astrazeneca, Chang Hui Fang, Holmquist Christopher, Phillips Eifion, Piser Timothy, Simpson Thomas, Urbanek Rebecca, Woods James, Xiong Hui, ASTRAZENECA, November 22, 2007: WO/2007/133155 (11 worldwide citation)

Nicotinic acetylcholine receptor ligands of Formula I, I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.


8
Ernst Glen, Phillips Eifion, Schmiesing Richard: Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.. Astrazeneca, June 15, 2005: EP1539764-A1 (4 worldwide citation)

Nicotinic acetylcholine receptor agonists of formula I wherein a, b, c, D and R are as defined in the specification, enantiomers, pharmaceutically- acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same in the treatment or prophylaxis of psychotic ...


9
Phillips Eifion: Spirofuropyridine aryl derivatives. Astrazeneca, Astrazeneca, Phillips Eifion, GLOBAL INTELLECTUAL PROPERTY, May 12, 2005: WO/2005/042538 (3 worldwide citation)

Compounds of formula (I): and pharmaceutically-acceptable salts thereof, wherein: Ar is a moiety of formula (II) or (III): and A, B, and R1 are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.


10
Dorff Peter, Gordon John, Heys John Richard, Keith Richard A, Mccarthy Dennis J, Phillips Eifion, Smith Mark A: Ligands. Astrazeneca, Astrazeneca, Dorff Peter, Gordon John, Heys John Richard, Keith Richard A, Mccarthy Dennis J, Phillips Eifion, Smith Mark A, GLOBAL INTELLECTUAL PROPERTY, April 7, 2005: WO/2005/030778 (3 worldwide citation)

A radioactive compound having the formula (I), where R1 and Ar are as defined in the specification, pharmaceutically-acceptable salts thereof, compositions containing such compounds and uses thereof in diagnosis of conditions wherein the &agr;7 nicotinic receptor is involved.